6533b7d4fe1ef96bd1261ea0

RESEARCH PRODUCT

Redox imbalances in ageing and metabolic alterations: Implications in cancer and cardiac diseases. An overview from the working group of cardiotoxicity and cardioprotection of the Italian society of cardiology (SIC)

Claudia PennaPaolo SpallarossaPietro AmeriEleonora ArboscelloDaniela Di LisiCarlo G. TocchettiCiro SantoroConcetta ZitoAlessandra CuomoRoberta ManganaroGiuseppina NovoChristian Cadeddu DessalviValentina MercurioMartino Deidda

subject

Oncologymedicine.medical_specialtyPhysiologyClinical BiochemistryReview030204 cardiovascular system & hematologymedicine.disease_causeBiochemistry03 medical and health sciences0302 clinical medicineInternal medicineAgeing; Cancer; Cardiovascular disease; Cardiovascular toxicity from anticancer drugs; Metabolic syndromemedicineEndothelial dysfunctionRisk factorMolecular BiologySedentary lifestyleCancerCardiotoxicitybusiness.industrylcsh:RM1-950CancerCell Biologymedicine.diseaseCardiovascular diseaseMetabolic syndromeAgeingCardiovascular toxicity from anticancer drugslcsh:Therapeutics. PharmacologyCardiovascular toxicity from anticancer drug030220 oncology & carcinogenesisHeart failureMetabolic syndromebusinessOxidative stress

description

Metabolic syndrome (MetS) is a well established risk factor for cardiovascular (CV) diseases. In addition, several studies indicate that MetS correlates with the increased risk of cancer in adults. The mechanisms linking MetS and cancer are not fully understood. Several risk factors involved in MetS are also cancer risk factors, such as the consumption of high calorie-food or high fat intake, low fibre intake, and sedentary lifestyle. Other common aspects of both cancer and MetS are oxidative stress and inflammation. In addition, some anticancer treatments can induce cardiotoxicity, including, for instance, left ventricular (LV) dysfunction and heart failure (HF), endothelial dysfunction and hypertension. In this review, we analyse several aspects of MetS, cancer and cardiotoxicity from anticancer drugs. In particular, we focus on oxidative stress in ageing, cancer and CV diseases, and we analyse the connections among CV risk factors, cancer and cardiotoxicity from anticancer drugs.

10.3390/antiox9070641http://hdl.handle.net/11567/1026111